ACUTAAS Acutaas Chemicals Q4 FY26 results (Jan–Mar 2026) and concall
Acutaas Chemicals reported a strong Q4 FY26 with significant revenue and PAT growth, driven by its CDMO and Advanced Pharmaceutical Intermediates segments. The company is actively diversifying into battery chemicals and semiconductors, with new products and capacity expansions underway. Despite global supply chain challenges, management is confident in maintaining margins and projects 25% revenue growth for FY27, supported by a robust pipeline and strategic infrastructure development.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 38.8%, net profit up 117.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 271 | 304 | 206 | 305 | 391 +44% | 422 +39% |
| EBITDA | 67 | 84 | 51 | 97 | 154 +130% | 181 +115% |
| Net profit | 45 | 63 | 45 | 73 | 112 +149% | 137 +117% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
